ArticleFrontiers in ophthalmology2026
Peripapillary hyperreflective ovoid mass-like structure in arteritic versus nonarteritic anterior ischemic optic neuropathy.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) and High-Risk Cardiovascular Events.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A peripapillary hyperreflective ovoid mass-like structure (PHOMS) is an optical coherence tomography (OCT) specific finding associated with axoplasmic stasis in various optic neuropathies. Its occurrence in arteritic anterior ischemic optic neuropathy (A-AION) has not previously been described, and its prevalence and structural implications across AION subtypes remain incompletely understood. Materials & methods: In this exploratory retrospective, age-matched study, patients with A-AION and nonarteritic AION (NA-AION) enrolled in two prior prospective studies between March 2021 and August 2024 were included. All eyes had undergone high-resolution spectral-domain OCT imaging of the optic nerve head as well as visual acuity assessment on first visit of diagnosis. PHOMS was identified according to Optic Disc Drusen Studies (ODDS) Consortium criteria. Results: Twenty-two patients (22 eyes) were included, with 11 eyes in each AION subtype. PHOMS was observed in both A-AION and NA-AION. PHOMS was identified in 4 of 11 eyes (36.4%) with A-AION compared with 2 of 11 eyes (18.2%) with NA-AION. The estimated odds ratio for PHOMS presence in A-AION compared with NA-AION was 2.57 (95% CI, 0.36-18.33; p = 0.635). Bruch's membrane opening diameter was similar between groups (A-AION: 1546.78 ± 134.14 μm; NA-AION: 1507.27 ± 133.95 μm), while mean peripapillary retinal nerve fiber layer thickness was larger in A-AION than in NA-AION. No differences were observed in macular ganglion cell layer volume, other retinal layer volumes, total retinal volume, or visual acuity between subtypes. Discussion: The observation of PHOMS across ischemic optic neuropathy subtypes suggests that PHOMS in AION may reflect axoplasmic disturbance related to the ischemic insult itself rather than the underlying disease etiology, although confirmation in larger, prospective studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.